论文部分内容阅读
2007年4月30日,欧洲最大的制药商赛诺菲-安万特(NYSE:SNY)宣布FDA已批准其新型胰岛素笔Lantus SoloStar在美上市,用于Ⅰ型和Ⅱ型糖尿
On April 30, 2007, sanofi-aventis (NYSE: SNY), Europe’s largest drug maker, announced that FDA has approved the new insulin pen Lantus SoloStar to be available in the United States for Type 1 and Type 2 diabetes